EARLY ERCP IN PATIENTS WITH ACUTE CHOLANGITIS WAS ASSOCIATED WITH SHORTER HOSPITAL STAY

Introduction:
It is controversial whether glucagon-like peptide 1 (GLP-1) receptor agonists (RA) are associated with adverse pancreatic, gallbladder or biliary outcomes. Using a global aggregated electronic health record database, we assessed if starting patients with T2DM on GLP-1 RAs was associated with an increased risk of pancreaticobiliary disease.
Materials and Methods:
A retrospective query was constructed on the TriNetX platform querying 91 healthcare organizations from 12 countries. We identified all non-deceased adult patients with active records who had T2DM at the time of GLP-1 RA initiation between 2002 to 2022. The control group was patients with T2DM at the time of sodium-glucose co-transport 2 inhibitors (SGLT2i) initiation. Patients in both cohorts were excluded if they had a history of pancreatic or hepatobiliary disease or had undergone any procedure related to this system up until 1 day after the index event. Patients were also excluded if they ever had a neoplasm of any digestive organ or a history of malignant neuroendocrine tumors. Furthermore, both groups were exclusive and propensity-matched based on key factors that would predict GLP-1 RA vs. SGLT2i initiation, as well as risk factors for pancreatic and hepatobiliary disease (Table 1). We extracted the number of patients who were diagnosed with acute pancreatitis or cholelithiasis, as well as those who had a first-time diagnosis of cholecystitis, chronic pancreatitis, or underwent cholecystectomy. We combined bile duct stones, bile duct obstruction, biliary colic, and biliary fistula under a single outcome of biliary disease. Finally, we extracted the number of patients who underwent first-time endoscopic retrograde cholangiopancreatography (ERCP) as well as the number of hospitalizations or emergency visits. All outcomes were identified between 1 day after the index event and up to 3 years. Odds ratios were calculated within the TriNetX Analytics Platform with significance set at a 2-sided P value <0.05.
Results:
After propensity matching, there were 206, 717 patients on GLP-1 RA without SGLT2i and vice versa. Within 3 years of initiating GLP-1 RA, (1) patients were at increased risk of developing cholecystitis (OR 1.42; 95% CI 1.25-1.61) and cholelithiasis (1.32; 1.24-1.39), and undergoing cholecystectomy (1.41; 1.24-1.61); (2) patients also had an increased risk of emergency department visits (1.27; 1.24-1.30) and hospitalization (1.14; 1.13-1.16); these associations persisted with initial A1c <7%; however, (3) patients were not more likely to experience a biliary disease outcome or acute/chronic pancreatitis, or undergo an ERCP.
Conclusion:
GLP-1 RAs are associated with developing cholecystitis and cholelithiasis, as well as undergoing a cholecystectomy; however, they are not associated with acute or chronic pancreatitis or other biliary disease events.

Background: Acute cholangitis is caused by a bacterial infection in the biliary tract, most commonly due to choledocholithiasis and malignant strictures. Previous studies have shown a 30-day mortality in patients with acute cholangitis of 2.6-16%. The importance of early ERCP in these patients is controversial. The aims of the study were to examine the prognosis of patients with acute cholangitis and compare outcomes in those who had early ERCP within 24 hours from diagnosis and those who had ERCP undertaken later.
Methods: A prospectively maintained endoscopic database was used to identify all patients who underwent ERCP between 2010 and 2021, in a university hospital setting which has a catchment area of around 320,000 inhabitants. Medical records of patients diagnosed with cholangitis (k83.0) and calculus of bile duct with cholangitis (k80.3) according to ICD-10 diagnostic codes were reviewed. The Tokyo guidelines from 2018 were used to verify the diagnosis of acute cholangitis and to determine the severity grading. Sepsis was analysed and defined by the Sepsis-3 criteria from 2016. Early ERCP was defined as ERCP procedure undertaken within 24 hours from diagnosis.
Results: Among 2616 patients who underwent ERCP, 240 (9%) fulfilled the inclusion criteria, of whom 107 were women (45%), median age 72 years. The most common cause of acute cholangitis was gallstones in 180 (75%) of cases, 46 (19%) had a malignant cause and 14 (6%) other causes. A total of 61 (25%) of the patients underwent ERCP within 24 hours from diagnosis. Overall 30-day mortality was 3.3% (n=8), mortality was similar in the early ERCP group (4.9%) and those who had ERCP later (2.8%). Patients who underwent early ERCP were more likely to have severe acute cholangitis than those who underwent ERCP later (31% vs 18%, p=0.047) but had a shorter median hospital stay (4 vs. 6 days, p=0.006). In all 54 (23%) patients had sepsis during their hospital stay, 33% among those who had early ERCP vs. 19% among those who underwent ERCP later (p=0.033)
Conclusion: Thirty-day mortality was only 3% in patients with acute cholangitis. ERCP was undertaken in 25% of patients within 24 hours, more commonly in those with more severe symptoms. Despite increased severity in those who underwent ERCP early, this was associated with a shorter hospital stay, which suggests benefits of performing early ERCP in patients with acute severe cholangitis.